Free Trial

FORA Capital LLC Purchases Shares of 12,935 Arcellx, Inc. (NASDAQ:ACLX)

Arcellx logo with Medical background

FORA Capital LLC acquired a new position in shares of Arcellx, Inc. (NASDAQ:ACLX - Free Report) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 12,935 shares of the company's stock, valued at approximately $1,080,000.

A number of other large investors have also made changes to their positions in the stock. Vanguard Group Inc. raised its position in Arcellx by 8.1% in the first quarter. Vanguard Group Inc. now owns 2,228,856 shares of the company's stock worth $155,017,000 after purchasing an additional 167,037 shares in the last quarter. Great Point Partners LLC lifted its position in shares of Arcellx by 64.0% during the 2nd quarter. Great Point Partners LLC now owns 492,000 shares of the company's stock worth $27,153,000 after buying an additional 192,000 shares during the period. Affinity Asset Advisors LLC grew its position in Arcellx by 53.3% in the second quarter. Affinity Asset Advisors LLC now owns 460,000 shares of the company's stock valued at $25,387,000 after acquiring an additional 160,000 shares during the period. Charles Schwab Investment Management Inc. grew its position in Arcellx by 4.5% in the third quarter. Charles Schwab Investment Management Inc. now owns 328,093 shares of the company's stock valued at $27,399,000 after acquiring an additional 14,200 shares during the period. Finally, Victory Capital Management Inc. raised its stake in Arcellx by 20.4% during the second quarter. Victory Capital Management Inc. now owns 283,872 shares of the company's stock worth $15,667,000 after acquiring an additional 48,006 shares in the last quarter. Institutional investors and hedge funds own 96.03% of the company's stock.

Insiders Place Their Bets

In related news, insider Christopher Heery sold 27,451 shares of Arcellx stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $67.03, for a total transaction of $1,840,040.53. Following the transaction, the insider now owns 9,278 shares of the company's stock, valued at $621,904.34. This trade represents a 74.74 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Kavita Patel sold 15,238 shares of the business's stock in a transaction that occurred on Monday, November 11th. The shares were sold at an average price of $105.92, for a total transaction of $1,614,008.96. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 97,873 shares of company stock worth $8,621,767. Insiders own 6.24% of the company's stock.

Arcellx Trading Down 2.1 %

Shares of NASDAQ:ACLX traded down $1.89 during trading on Thursday, hitting $89.07. 353,698 shares of the company's stock were exchanged, compared to its average volume of 479,664. The firm has a 50-day moving average price of $87.97 and a two-hundred day moving average price of $69.69. Arcellx, Inc. has a 1-year low of $46.42 and a 1-year high of $107.37. The firm has a market cap of $4.82 billion, a P/E ratio of -125.45 and a beta of 0.27.

Arcellx (NASDAQ:ACLX - Get Free Report) last posted its quarterly earnings results on Thursday, November 7th. The company reported ($0.48) earnings per share for the quarter, beating analysts' consensus estimates of ($0.54) by $0.06. Arcellx had a negative return on equity of 8.28% and a negative net margin of 25.94%. The company had revenue of $26.03 million for the quarter, compared to the consensus estimate of $35.21 million. As a group, research analysts predict that Arcellx, Inc. will post -1.49 EPS for the current year.

Wall Street Analyst Weigh In

ACLX has been the topic of several analyst reports. Robert W. Baird upped their target price on shares of Arcellx from $77.00 to $106.00 and gave the stock an "outperform" rating in a report on Wednesday, November 6th. Redburn Atlantic initiated coverage on shares of Arcellx in a research note on Tuesday, October 8th. They set a "buy" rating and a $109.00 price objective on the stock. Morgan Stanley lifted their target price on shares of Arcellx from $81.00 to $106.00 and gave the company an "overweight" rating in a research note on Wednesday, November 6th. HC Wainwright increased their price target on Arcellx from $80.00 to $95.00 and gave the stock a "buy" rating in a research report on Wednesday, November 6th. Finally, Piper Sandler lifted their price objective on Arcellx from $91.00 to $115.00 and gave the company an "overweight" rating in a research report on Friday, November 8th. Thirteen equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Buy" and a consensus target price of $103.08.

View Our Latest Stock Report on ACLX

About Arcellx

(Free Report)

Arcellx, Inc, together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM).

Featured Articles

Institutional Ownership by Quarter for Arcellx (NASDAQ:ACLX)

Should you invest $1,000 in Arcellx right now?

Before you consider Arcellx, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Arcellx wasn't on the list.

While Arcellx currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Broadcom Hits $1 Trillion – Can This AI Powerhouse Go Higher?

Broadcom Hits $1 Trillion – Can This AI Powerhouse Go Higher?

AVGO is up 30% since earnings: could Broadcom be the next member of the Magnificent Seven? Can it sustain this momentum or is a pullback on the horizon?

Related Videos

Why Meta Is Still a Top Stock Pick for 2025
Meta Platforms Tops Most Upgraded Stocks List—Here’s What to Expect
Alphabet Gaining Momentum: Can It Reach $200 by December?

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines